CoChat

Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease

Open access
Thorp, Audrey, Stine, Jonathan G. · 2020 · Current Hepatology Reports
Cited by 50

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of global liver disease. Because current pharmacologic treatments are ineffective, lifestyle change centered on exercise remains the most effective NAFLD treatment. The aim of this systematic review is to summarize and evaluate the current evidence supporting the use of exercise training as a medical treatment for adult patients with NAFLD. At least 150 min each week of moderate intensity exercise of any type can improve NAFLD, both with and without modest weight loss. Exercise training reduces hepatic steatosis and liver inflammation, favorably changes body composition, improves vascular endothelial function, increases cardiorespiratory fitness, and can lead to histologic response. To date, exercise-based NAFLD trials are limited by small sample size and significant heterogeneity. While several key questions remain unanswered, exercise training will always be an important part of the medical management of patients with NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11901-020-00543-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 43

  1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. · DOI · Paper page
  2. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344–53. · DOI · Paper page
  3. Lam B, Kurzke K, Younossi Z. The clinical and economic burden of nonalcoholic steatohepatitis. Curr Hepatol Rep. 2018;17(4):345–9. · DOI
  4. • Croci I, Coombes JS, Bucher Sandbakk S, Keating SE, Nauman J, Macdonald GA, et al. Non-alcoholic fatty liver disease: prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. Prog Cardiovasc Dis. 2019;62(2):127–34. · DOI · Paper page
  5. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. · DOI · Paper page
  6. • Mazzotti A, Caletti MT, Brodosi L, di Domizio S, Forchielli ML, Petta S, et al. An internet-based approach for lifestyle changes in patients with NAFLD: two-year effects on weight loss and surrogate markers. J Hepatol. 2018;69(5):1155–63. · DOI · Paper page
  7. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79–104. · DOI · Paper page
  8. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55(6):1738–45. · DOI · Paper page
  9. Johari MI, Yusoff K, Haron J, Nadarajan C, Ibrahim KN, Wong MS, et al. A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease. Sci Rep. 2019;9(1):11232. · DOI · Paper page
  10. Yamamoto M, Iwasa M, Iwata K, Kaito M, Sugimoto R, Urawa N, et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007;22(4):498–503. · DOI · Paper page
  11. Clausen JSR, Marott JL, Holtermann A, Gyntelberg F, Jensen MT. Midlife cardiorespiratory fitness and the long-term risk of mortality. J Am Coll Cardiol. 2018;72(9):987–95. · DOI · Paper page
  12. Strasser B, Burtscher M. Survival of the fittest: VO(2)max, a key predictor of longevity? Front Biosci (Landmark Ed). 2018;23:1505–16. · DOI · Paper page
  13. Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1):e000106. · DOI · Paper page
  14. • Argo CK, Stine JG, Henry ZH, Lackner C, Patrie JT, Weltman AL, et al. Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2018;48(3):290–9. · DOI · Paper page
  15. Austin P, Gerber L, Paik JM, Price JK, Escheik C, Younossi ZM. Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. J Sports Med Phys Fitness. 2019;59(8):1376–88. · DOI
  16. Pugh CJ, et al. Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease. Int J Obes. 2016;40(12):1927–30. · DOI
  17. Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol. 2014;6(8):570–9. · DOI
  18. Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia. 2007;50(6):1127–39. · DOI · Paper page
  19. Stine JG, Xu D, Schmitz K, Sciamanna C, Kimball SR. Exercise attenuates ribosomal protein six phosphorylation in fatty liver disease. Dig Dis Sci. 2020. · DOI · Paper page
  20. Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 2016;311(4):E730–e740. · DOI · Paper page
  21. Woo JH, Shin KO, Lee YH, Jang KS, Bae JY, Roh HT. Effects of treadmill exercise on skeletal muscle mTOR signaling pathway in high-fat diet-induced obese mice. J Phys Ther Sci. 2016;28(4):1260–5. · DOI
  22. Ropelle ER, Fernandes MFA, Flores MBS, Ueno M, Rocco S, Marin R, et al. Central exercise action increases the AMPK and mTOR response to leptin. PLoS One. 2008;3(12):e3856. · DOI · Paper page
  23. Piguet AC, Saran U, Simillion C, Keller I, Terracciano L, Reeves HL, et al. Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. J Hepatol. 2015;62(6):1296–303. · DOI
  24. • Glass OK, Radia A, Kraus WE, Abdelmalek MF. Exercise training as treatment of nonalcoholic fatty liver disease. J Funct Morphol Kinesiol. 2017;2(4):35. · DOI
  25. García-Hermoso A, Ramírez-Vélez R, Ramírez-Campillo R, Peterson MD, Martínez-Vizcaíno V. Concurrent aerobic plus resistance exercise versus aerobic exercise alone to improve health outcomes in paediatric obesity: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):161–6. · DOI · Paper page
  26. Singh AK, Kaur N, Kaushal S, Tyagi R, Mathur D, Sivapuram MS, et al. Partitioning of radiological, stress and biochemical changes in pre-diabetic women subjected to Diabetic Yoga Protocol. Diabetes Metab Syndr. 2019;13(4):2705–13. · DOI
  27. Keymasi Z, Sadeghi A, Pourrazi H. Effect of pilates training on hepatic fat content and liver enzymes in men with non-alcoholic fatty liver disease in Qazvin. J Shahrekord Univ Med Sci. 2020;22(1):22–8. · DOI
  28. Liu X, Miller YD, Burton NW, Brown WJ. A preliminary study of the effects of Tai Chi and Qigong medical exercise on indicators of metabolic syndrome, glycaemic control, health-related quality of life, and psychological health in adults with elevated blood glucose. Br J Sports Med. 2010;44(10):704–9. · DOI · Paper page
  29. • Abdelbasset WK, Tantawy SA, Kamel DM, Alqahtani BA, Elnegamy TE, Soliman GS, et al. Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease: a comparative randomized controlled trial. Medicine (Baltimore). 2020;99(10):e19471. · DOI · Paper page
  30. Nath P, Panigrahi MK, Sahu MK, Narayan J, Sahoo RK, Patra AA, et al. Effect of exercise on NAFLD and its risk factors: comparison of moderate versus low intensity exercise. J Clin Transl Hepatol. 2020;8(2):120. https://doi.org/10.14218/JCTH.2019.00012. · DOI
  31. Pugh CJ, et al. Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab. 2013;305(1):E50–8. · DOI · Paper page
  32. Jia GY, Han T, Gao L, Wang L, Wang SC, Yang L, et al. Effect of aerobic exercise and resistance exercise in improving non-alcoholic fatty liver disease: a randomized controlled trial. Zhonghua Gan Zang Bing Za Zhi. 2018;26(1):34–41.
  33. Kleiner DE, Brunt EM, van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. · DOI · Paper page
  34. Filozof C, Chow SC, Dimick-Santos L, Chen YF, Williams RN, Goldstein BJ, et al. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic. Hepatol Commun. 2017;1(7):577–85. · DOI · Paper page
  35. Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017–23. · DOI · Paper page
  36. Lee SB, Park GM, Lee JY, Lee BU, Park JH, Kim BG, et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study. J Hepatol. 2018;68(5):1018–24. · DOI
  37. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57(3):363–9. · DOI · Paper page
  38. Yeboah J, Sutton-Tyrrell K, Mcburnie MA, Burke GL, Herrington DM, Crouse JR. Association between brachial artery reactivity and cardiovascular disease status in an elderly cohort: the cardiovascular health study. Atherosclerosis. 2008;197(2):768–76. · DOI
  39. Gonzalez-Paredes FJ, Hernández Mesa G, Morales Arraez D, Marcelino Reyes R, Abrante B, Diaz-Flores F, et al. Contribution of cyclooxygenase end products and oxidative stress to intrahepatic endothelial dysfunction in early non-alcoholic fatty liver disease. PLoS One. 2016;11(5):e0156650. · DOI · Paper page
  40. Sapmaz F, Uzman M, Basyigit S, Ozkan S, Yavuz B, Yeniova A, et al. Steatosis grade is the most important risk factor for development of endothelial dysfunction in NAFLD. Medicine (Baltimore). 2016;95(14):e3280. · DOI · Paper page
  41. Thakur ML, Sharma S, Kumar A, Bhatt SP, Luthra K, Guleria R, et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis. 2012;223(2):507–11. · DOI
  42. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449–57. · DOI · Paper page
  43. Lonardo A, Nascimbeni F, Ballestri S, Fairweather DL, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70(4):1457–69. · DOI · Paper page

Cited by

See all 50

Metadata

Authors
Thorp, A., & Stine, J. G.
Venue
Current Hepatology Reports
Published
2020-09-09
Volume
19
Issue
4
Pages
402-411
ISSN
  • 1540-3416 (ISSN-L)
  • 2195-9595
OpenAlex
W3085333043
Cited by
50
References
42
FWCI
4.30
Type
journal article
Language
en
Open access
green
Licence
Funders
National Institutes of Health (L30 DK118601)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.